Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis b infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials

Marcellin, PatrickGane, Edward J.Flisiak, RobertTrinh, Huy N.Petersen, JoergGürel, SelimKaita, Kelly D.Kotzev, Iskren A.Tsai, NaokyFlaherty, John F.Schall, Raul E. AguilarKitrinos, Kathryn M.Subramanian, ManiMcHutchison, John G.George, JacobJanssen, Harry L.Buti, Maria2024-08-152024-08-152014-01-010270-9139https://hdl.handle.net/11452/44079Bu çalışma, 07-11, Kasım 2014 tarihlerinde Boston[Amerika]’da düzenlenen 65. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessScience & technologyLife sciences & biomedicineGastroenterology & hepatologyLong term treatment with tenofovir disoproxil fumarate for chronic hepatitis b infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trialsMeeting Abstract000344483801163313A314A601527-3350